Lp(a) is a useful biomarker for helping to identify patients with well controlled LDL-C who are still at risk of coronary artery disease (CAD), according to data from the Young Heart study of patients <60 years with CAD.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
